AI assistant
GENEDRIVE PLC — Director's Dealing 2019
Apr 5, 2019
7668_dirs_2019-04-05_855a63b8-7031-43d0-b553-daefa225dfa2.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 2703V
Genedrive PLC
05 April 2019
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 1,330,000 ordinary shares of 1.5p each in the capital of the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
David Budd CEO
Matthew Fowler CFO
Gino Miele R&D Director
Gordon Powell Commercial Director
Colleen Pythian Director of Quality & Regulation
Warren Berry Operations Director
2.
Reason for the notification
a.
Position/status
1.
a.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
genedrive plc
b.
LEI
213800ZYODIRZ87Y4K14
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type
of instrument
Identification code
Options over ordinary shares of 1.5 pence each
b.
Nature of the transaction
Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017.
c.
Price(s) and volume(s)
| Option price(s) | Volume(s) | |
| David Budd | 23.5p | 540,000 |
| Matthew Fowler | 23.5p | 340,000 |
| Gino Miele | 23.5p | 150,000 |
| Gordon Powell | 23.5p | 150,000 |
| Colleen Pythian | 23.5p | 75,000 |
| Warren Berry | 23.5p | 75,000 |
d.
Aggregated information
· Aggregated volume
· Price
N/A
e.
Date of the transaction
2019-April-04; UTC time
f.
Place of the transaction
Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options
For further details please contact:
| genedrive plc | +44 (0)161 989 0245 |
| David Budd: CEO | |
| Matthew Fowler: CFO | |
| Peel Hunt LLP | +44 (0)207 418 8900 |
| James Steel / Oliver Jackson | |
| Stanford Capital Partners Limited | +44 (0) 20 3815 8880 |
| Patrick Claridge / John Howes | |
| Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or [email protected] |
| Paul McManus / Anna Dunphy |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHEAXLSEAPNEEF